Pharmaceutical manufacturers of Insulin

Founded in 1978, Biocon Limited is the largest biotechnology company in India and a leading company in Asia, focusing on biopharmaceuticals and research services. It is an integrated and innovation-driven enterprise that provides affordable solutions for chronic diseases globally. The company develops, manufactures, and offers a diverse portfolio of Small Molecules APIs & Formulations and Complex Biologics, including Novels and Biosimilars like MAbs, rh-insulin& Insulin Analogs. Among its notable products are the world's first Pichia-based recombinant human Insulin, INSUGEN, Glargine, BASALOG, and India's first biologic BioMAb-EGFR for head and neck cancer. Additionally, it has developed Itolizumab, a 'first in class' anti-CD6 monoclonal antibody, introduced as Alzumab for psoriasis in India in 2013.

Established in 1998, Gan & Lee Pharmaceuticals is an advanced biopharmaceutical company specialized in the exploration, formulation, manufacturing, and marketing of insulin and its derivatives, holding a prominent position in the diabetes sector in China. Since its establishment, Gan & Lee has directed its efforts toward insulin synthesis. In 1998, Gan & Lee achieved a significant milestone by creating the initial domestically produced biosynthetic human insulin, a development acknowledged as one of China's top 10 scientific and technological advancements by the Chinese Academy of Sciences and Engineering. Up to now, Gan & Lee has introduced several comparable biosimilar insulin derivative products.

elm-plastic GmbH is a German family-owned business that was established in 1969. Operating on a production area of 4500 square meters, we manufacture high-quality plastic components to a technically advanced standard with a workforce of approximately 120 employees working in three shifts. Our product line primarily comprises of packaging products for pharmaceuticals and dosing instruments for both human and veterinary medicine. Our satisfied customer base includes renowned international pharmacists and bottlers. These products are the result of longstanding collaboration between pharmacists, bottlers, users, and our development department.

For more than 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems, like our insulin pens. Our treatments today are benefiting millions of people living with diabetes, obesity, and rare blood and endocrine diseases. From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.

Wockhardt UK (WUK) operates as a diverse pharmaceutical company, serving as a significant provider of healthcare products to the NHS through hospitals, multiple retail pharmacy chains, and wholesalers. It is currently experiencing an exciting period with thriving export and contract manufacturing divisions. Leveraging the global strength, research base, and impressive product pipeline of its parent company, Wockhardt UK is well-positioned for future growth.

Kalbe has come a long way since its humble beginnings in a garage to emerge as the primary pharmaceutical company in Indonesia. Through both natural growth and mergers & acquisitions, Kalbe has broadened its business interests and evolved into a provider of comprehensive healthcare solutions through its four business divisions: the Prescription Pharmaceutical Division (23% contribution), Consumer Health Division (17% contribution), Nutritionals Division (30% contribution), and Distribution and Logistics Division (30% contribution).

Tonghua Dongbao Group Import & Export Co.,Ltd. (Formerly known as Dongbao Group Imp & Exp Co.,Ltd.; Tonghua Dongbao Imp &Exp Co., Ltd.) was founded in 1993 and is a wholly owned subsidiary of Dongbao Group. Serving as the primary entity for Dongbao Group's international operations, it functions as the central administrative unit for the group's overseas economic and trade activities.

Aradigm is actively involved in fulfilling the commitment to developing inhalation medication products that could potentially transform the quality of life for patients with severe pulmonary conditions. Since 1991, the organization has assembled an exceptional group of researchers, technicians, and medical specialists who have been leading the way in the creation of innovative inhalation delivery products. This team, for instance, spearheaded the AERx® pulmonary delivery platform, which underwent testing in numerous patients using various medications and biologics such as insulin, fentanyl, erythropoietin, and nicotine.